private:eurekainc
|
497678
|
Nov 18th, 2019 12:00AM
|
Eureka Therapeutics, Inc
|
3.5K
|
53.00
|
Open
|
Biotechnology
|
Nov 18th, 2019 04:13PM
|
Nov 18th, 2019 04:13PM
|
Eureka Therapeutics is a privately held biotechnology company located in the San Francisco Bay Area, focused on breakthrough immunotherapies for the treatment of cancer.
Utilizing our antibody drug discovery and engineering technologies, we are advancing safe and effective therapies for targeting previously inaccessible cancer antigens. We have built an early stage pipeline of innovative drugs, with the most advanced candidates at pre-clinical stage.
Eureka Therapeutics is a leader in the discovery of novel antibody immunotherapies. We utilize a paradigm-changing technology platform to develop fully-human antibodies against intracellular cancer antigens. In collaboration with Memorial Sloan-Kettering Cancer Center, we were the first-to-demonstrate in vivo efficacy of a human IgG1 antibody against an intracellular cancer antigen. Our most advanced program is at preclinical stage and being developed in partnership with Novartis.
|
Open
|
Therapeutic Antibodies, Immunotherapy, Oncology, Phage Display, CART, Engineered T cell therapy, Cell Therapy, Hepatocellular Carcinoma, Non-Hodgkin's Lymphoma
|
Open
|
5858 Horton Street, Suite 370
|
Emeryville
|
CA
|
US
|
94608
|
|
Eureka Therapeutics
|
|
|
private:eurekainc
|
497678
|
Nov 17th, 2019 12:00AM
|
Eureka Therapeutics, Inc
|
3.5K
|
53.00
|
Open
|
Biotechnology
|
Nov 17th, 2019 04:39PM
|
Nov 17th, 2019 04:39PM
|
Eureka Therapeutics is a privately held biotechnology company located in the San Francisco Bay Area, focused on breakthrough immunotherapies for the treatment of cancer.
Utilizing our antibody drug discovery and engineering technologies, we are advancing safe and effective therapies for targeting previously inaccessible cancer antigens. We have built an early stage pipeline of innovative drugs, with the most advanced candidates at pre-clinical stage.
Eureka Therapeutics is a leader in the discovery of novel antibody immunotherapies. We utilize a paradigm-changing technology platform to develop fully-human antibodies against intracellular cancer antigens. In collaboration with Memorial Sloan-Kettering Cancer Center, we were the first-to-demonstrate in vivo efficacy of a human IgG1 antibody against an intracellular cancer antigen. Our most advanced program is at preclinical stage and being developed in partnership with Novartis.
|
Open
|
Therapeutic Antibodies, Immunotherapy, Oncology, Phage Display, CART, Engineered T cell therapy, Cell Therapy, Hepatocellular Carcinoma, Non-Hodgkin's Lymphoma
|
Open
|
5858 Horton Street, Suite 370
|
Emeryville
|
CA
|
US
|
94608
|
|
Eureka Therapeutics
|
|
|
private:eurekainc
|
497678
|
Nov 16th, 2019 12:00AM
|
Eureka Therapeutics, Inc
|
3.5K
|
53.00
|
Open
|
Biotechnology
|
Nov 16th, 2019 04:33PM
|
Nov 16th, 2019 04:33PM
|
Eureka Therapeutics is a privately held biotechnology company located in the San Francisco Bay Area, focused on breakthrough immunotherapies for the treatment of cancer.
Utilizing our antibody drug discovery and engineering technologies, we are advancing safe and effective therapies for targeting previously inaccessible cancer antigens. We have built an early stage pipeline of innovative drugs, with the most advanced candidates at pre-clinical stage.
Eureka Therapeutics is a leader in the discovery of novel antibody immunotherapies. We utilize a paradigm-changing technology platform to develop fully-human antibodies against intracellular cancer antigens. In collaboration with Memorial Sloan-Kettering Cancer Center, we were the first-to-demonstrate in vivo efficacy of a human IgG1 antibody against an intracellular cancer antigen. Our most advanced program is at preclinical stage and being developed in partnership with Novartis.
|
Open
|
Therapeutic Antibodies, Immunotherapy, Oncology, Phage Display, CART, Engineered T cell therapy, Cell Therapy, Hepatocellular Carcinoma, Non-Hodgkin's Lymphoma
|
Open
|
5858 Horton Street, Suite 370
|
Emeryville
|
CA
|
US
|
94608
|
|
Eureka Therapeutics
|
|
|
private:eurekainc
|
497678
|
Nov 15th, 2019 12:00AM
|
Eureka Therapeutics, Inc
|
3.5K
|
53.00
|
Open
|
Biotechnology
|
Nov 15th, 2019 01:13PM
|
Nov 15th, 2019 01:13PM
|
Eureka Therapeutics is a privately held biotechnology company located in the San Francisco Bay Area, focused on breakthrough immunotherapies for the treatment of cancer.
Utilizing our antibody drug discovery and engineering technologies, we are advancing safe and effective therapies for targeting previously inaccessible cancer antigens. We have built an early stage pipeline of innovative drugs, with the most advanced candidates at pre-clinical stage.
Eureka Therapeutics is a leader in the discovery of novel antibody immunotherapies. We utilize a paradigm-changing technology platform to develop fully-human antibodies against intracellular cancer antigens. In collaboration with Memorial Sloan-Kettering Cancer Center, we were the first-to-demonstrate in vivo efficacy of a human IgG1 antibody against an intracellular cancer antigen. Our most advanced program is at preclinical stage and being developed in partnership with Novartis.
|
Open
|
Therapeutic Antibodies, Immunotherapy, Oncology, Phage Display, CART, Engineered T cell therapy, Cell Therapy, Hepatocellular Carcinoma, Non-Hodgkin's Lymphoma
|
Open
|
5858 Horton Street, Suite 370
|
Emeryville
|
CA
|
US
|
94608
|
|
Eureka Therapeutics
|
|
|
private:eurekainc
|
497678
|
Nov 13th, 2019 12:00AM
|
Eureka Therapeutics, Inc
|
3.4K
|
54.00
|
Open
|
Biotechnology
|
Nov 13th, 2019 01:35PM
|
Nov 13th, 2019 01:35PM
|
Eureka Therapeutics is a privately held biotechnology company located in the San Francisco Bay Area, focused on breakthrough immunotherapies for the treatment of cancer.
Utilizing our antibody drug discovery and engineering technologies, we are advancing safe and effective therapies for targeting previously inaccessible cancer antigens. We have built an early stage pipeline of innovative drugs, with the most advanced candidates at pre-clinical stage.
Eureka Therapeutics is a leader in the discovery of novel antibody immunotherapies. We utilize a paradigm-changing technology platform to develop fully-human antibodies against intracellular cancer antigens. In collaboration with Memorial Sloan-Kettering Cancer Center, we were the first-to-demonstrate in vivo efficacy of a human IgG1 antibody against an intracellular cancer antigen. Our most advanced program is at preclinical stage and being developed in partnership with Novartis.
|
Open
|
Therapeutic Antibodies, Immunotherapy, Oncology, Phage Display, CART, Engineered T cell therapy, Cell Therapy, Hepatocellular Carcinoma, Non-Hodgkin's Lymphoma
|
Open
|
5858 Horton Street, Suite 370
|
Emeryville
|
CA
|
US
|
94608
|
|
Eureka Therapeutics
|
|
|
private:eurekainc
|
497678
|
Nov 12th, 2019 12:00AM
|
Eureka Therapeutics, Inc
|
3.4K
|
54.00
|
Open
|
Biotechnology
|
Nov 12th, 2019 03:16PM
|
Nov 12th, 2019 03:16PM
|
Eureka Therapeutics is a privately held biotechnology company located in the San Francisco Bay Area, focused on breakthrough immunotherapies for the treatment of cancer.
Utilizing our antibody drug discovery and engineering technologies, we are advancing safe and effective therapies for targeting previously inaccessible cancer antigens. We have built an early stage pipeline of innovative drugs, with the most advanced candidates at pre-clinical stage.
Eureka Therapeutics is a leader in the discovery of novel antibody immunotherapies. We utilize a paradigm-changing technology platform to develop fully-human antibodies against intracellular cancer antigens. In collaboration with Memorial Sloan-Kettering Cancer Center, we were the first-to-demonstrate in vivo efficacy of a human IgG1 antibody against an intracellular cancer antigen. Our most advanced program is at preclinical stage and being developed in partnership with Novartis.
|
Open
|
Therapeutic Antibodies, Immunotherapy, Oncology, Phage Display, CART, Engineered T cell therapy, Cell Therapy, Hepatocellular Carcinoma, Non-Hodgkin's Lymphoma
|
Open
|
5858 Horton Street, Suite 370
|
Emeryville
|
CA
|
US
|
94608
|
|
Eureka Therapeutics
|
|
|
private:eurekainc
|
497678
|
Nov 11th, 2019 12:00AM
|
Eureka Therapeutics, Inc
|
3.4K
|
54.00
|
Open
|
Biotechnology
|
Nov 11th, 2019 03:14PM
|
Nov 11th, 2019 03:14PM
|
Eureka Therapeutics is a privately held biotechnology company located in the San Francisco Bay Area, focused on breakthrough immunotherapies for the treatment of cancer.
Utilizing our antibody drug discovery and engineering technologies, we are advancing safe and effective therapies for targeting previously inaccessible cancer antigens. We have built an early stage pipeline of innovative drugs, with the most advanced candidates at pre-clinical stage.
Eureka Therapeutics is a leader in the discovery of novel antibody immunotherapies. We utilize a paradigm-changing technology platform to develop fully-human antibodies against intracellular cancer antigens. In collaboration with Memorial Sloan-Kettering Cancer Center, we were the first-to-demonstrate in vivo efficacy of a human IgG1 antibody against an intracellular cancer antigen. Our most advanced program is at preclinical stage and being developed in partnership with Novartis.
|
Open
|
Therapeutic Antibodies, Immunotherapy, Oncology, Phage Display, CART, Engineered T cell therapy, Cell Therapy, Hepatocellular Carcinoma, Non-Hodgkin's Lymphoma
|
Open
|
5858 Horton Street, Suite 370
|
Emeryville
|
CA
|
US
|
94608
|
|
Eureka Therapeutics
|
|
|
private:eurekainc
|
497678
|
Nov 10th, 2019 12:00AM
|
Eureka Therapeutics, Inc
|
3.4K
|
54.00
|
Open
|
Biotechnology
|
Nov 10th, 2019 06:21PM
|
Nov 10th, 2019 06:21PM
|
Eureka Therapeutics is a privately held biotechnology company located in the San Francisco Bay Area, focused on breakthrough immunotherapies for the treatment of cancer.
Utilizing our antibody drug discovery and engineering technologies, we are advancing safe and effective therapies for targeting previously inaccessible cancer antigens. We have built an early stage pipeline of innovative drugs, with the most advanced candidates at pre-clinical stage.
Eureka Therapeutics is a leader in the discovery of novel antibody immunotherapies. We utilize a paradigm-changing technology platform to develop fully-human antibodies against intracellular cancer antigens. In collaboration with Memorial Sloan-Kettering Cancer Center, we were the first-to-demonstrate in vivo efficacy of a human IgG1 antibody against an intracellular cancer antigen. Our most advanced program is at preclinical stage and being developed in partnership with Novartis.
|
Open
|
Therapeutic Antibodies, Immunotherapy, Oncology, Phage Display, CART, Engineered T cell therapy, Cell Therapy, Hepatocellular Carcinoma, Non-Hodgkin's Lymphoma
|
Open
|
5858 Horton Street, Suite 370
|
Emeryville
|
CA
|
US
|
94608
|
|
Eureka Therapeutics
|
|
|
private:eurekainc
|
497678
|
Nov 9th, 2019 12:00AM
|
Eureka Therapeutics, Inc
|
3.4K
|
54.00
|
Open
|
Biotechnology
|
Nov 9th, 2019 05:48PM
|
Nov 9th, 2019 05:48PM
|
Eureka Therapeutics is a privately held biotechnology company located in the San Francisco Bay Area, focused on breakthrough immunotherapies for the treatment of cancer.
Utilizing our antibody drug discovery and engineering technologies, we are advancing safe and effective therapies for targeting previously inaccessible cancer antigens. We have built an early stage pipeline of innovative drugs, with the most advanced candidates at pre-clinical stage.
Eureka Therapeutics is a leader in the discovery of novel antibody immunotherapies. We utilize a paradigm-changing technology platform to develop fully-human antibodies against intracellular cancer antigens. In collaboration with Memorial Sloan-Kettering Cancer Center, we were the first-to-demonstrate in vivo efficacy of a human IgG1 antibody against an intracellular cancer antigen. Our most advanced program is at preclinical stage and being developed in partnership with Novartis.
|
Open
|
Therapeutic Antibodies, Immunotherapy, Oncology, Phage Display, CART, Engineered T cell therapy, Cell Therapy, Hepatocellular Carcinoma, Non-Hodgkin's Lymphoma
|
Open
|
5858 Horton Street, Suite 370
|
Emeryville
|
CA
|
US
|
94608
|
|
Eureka Therapeutics
|
|
|
private:eurekainc
|
497678
|
Nov 8th, 2019 12:00AM
|
Eureka Therapeutics, Inc
|
3.4K
|
54.00
|
Open
|
Biotechnology
|
Nov 8th, 2019 02:59PM
|
Nov 8th, 2019 02:59PM
|
Eureka Therapeutics is a privately held biotechnology company located in the San Francisco Bay Area, focused on breakthrough immunotherapies for the treatment of cancer.
Utilizing our antibody drug discovery and engineering technologies, we are advancing safe and effective therapies for targeting previously inaccessible cancer antigens. We have built an early stage pipeline of innovative drugs, with the most advanced candidates at pre-clinical stage.
Eureka Therapeutics is a leader in the discovery of novel antibody immunotherapies. We utilize a paradigm-changing technology platform to develop fully-human antibodies against intracellular cancer antigens. In collaboration with Memorial Sloan-Kettering Cancer Center, we were the first-to-demonstrate in vivo efficacy of a human IgG1 antibody against an intracellular cancer antigen. Our most advanced program is at preclinical stage and being developed in partnership with Novartis.
|
Open
|
Therapeutic Antibodies, Immunotherapy, Oncology, Phage Display, CART, Engineered T cell therapy, Cell Therapy, Hepatocellular Carcinoma, Non-Hodgkin's Lymphoma
|
Open
|
5858 Horton Street, Suite 370
|
Emeryville
|
CA
|
US
|
94608
|
|
Eureka Therapeutics
|
|
|